Non-Hodgkin Lymphoma | Specialty

FDA Approval for Axi-Cel in NHL

January 9th 2018

Need for Salvage Therapies in R/R NHL

January 9th 2018

Clinical Data Behind CAR T-Cell Therapies in ALL

January 9th 2018

Tisagenlecleucel for Relapsed/Refractory ALL

January 9th 2018

The Promise of CAR T-Cell Therapy for ALL

January 9th 2018

Mechanisms of Resistance for CAR T Therapy

January 9th 2018

Managing CAR T-Cell Therapy Toxicity

January 9th 2018

Practicality of CAR T Therapy

January 9th 2018

The Status of CAR T in Hematologic Malignancies

January 9th 2018

Dr. Martin on Trial of Oral Azacitidine Plus R-CHOP in High Risk DLBCL

January 6th 2018

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses a trial of the combination of oral azacitidine (CC-486) and R-CHOP in diffuse large B-cell lymphoma (DLBCL).

The Future Treatment of Follicular Lymphoma

January 5th 2018

Immunotherapy in the Treatment of Follicular Lymphoma

January 5th 2018

FL: Potential for SYK/JAK Inhibitors or Azacitidine

January 5th 2018

Novel Agents in FL: Unmet Needs and Potential Uses

January 5th 2018

Follicular Lymphoma: Novel Approaches With Rituximab

January 5th 2018

Follicular Lymphoma: Optimizing Novel Agent Therapy

January 5th 2018

Third-Line Treatment for FL: PI3 Kinase Inhibitors

January 5th 2018

Choosing Second-Line Therapy for Relapsed/Refractory FL

January 5th 2018

Predicting and Analyzing Response in Follicular Lymphoma

January 5th 2018

Challenging the Role of Maintenance Therapy in FL

January 5th 2018